FindTrial
Sign In

Comparative study of Shallakyadi and Trivrutadi Dhoompaan in the management of Kaphaja Pratishyay.

A prospective open label comparative clinical study to assess the efficacy of Shallakyadi Dhoompaan and Trivrutadi Dhoompaan in the management of Kaphaja Pratishyay for seven days. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113554
Enrollment
60
Registered
2026-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J310- Chronic rhinitis

Interventions

None listed

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patient with classical symptoms Of Kaphaj Pratishyay Nasa srava, Shiro gaurav, Kantha kandu. 2) Age between 20-50 years. 3) Patient indicated for dhoompaan karma. 4) Willingness to participate with written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patient below 20 and Above 50 years. 2. Patient with lung cancer,heart diseaes. 3. Pregnant women and lactating mothers will be excluded. 4. All other types of pratishyay 5. Patient who is contra indicated for Dhoompana.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of Shallakyadi Dhoompaan and Trivrutadi Dhoompaan in Kaphaja Pratishyay having symptoms of nasa strav, shirogaurawta, kantha kandu.Timepoint: On 8th Day of therapy—

Secondary

MeasureTime frame
1)To study about pratishyay from ayurveda literature. 2)To study about dhoompaan from ayurveda literature. 3)To study Shallakyadi Dravya from literature. 4)To study Trivrutadi Dravya from literature.Timepoint: On 8th Day of therapy—

Countries

India

Contacts

Public ContactDR DIPALI JAYWANT CHAVAN

Shree Saptashringi Ayurved Mahavidyalaya and Hospital, Nashik

sparsh.dipa@gmail.com9421607548

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026